Comparative Pharmacology

Head-to-head clinical analysis: BRETYLIUM TOSYLATE versus BRETYLIUM TOSYLATE IN DEXTROSE 5.

Peer-Reviewed Evidence

Differential Analysis

BRETYLIUM TOSYLATE vs BRETYLIUM TOSYLATE IN DEXTROSE 5%

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

BRETYLIUM TOSYLATE

Antiarrhythmic (Class III)

Category C

BRETYLIUM TOSYLATE IN DEXTROSE 5%

Antiarrhythmic (Class III)

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Bretylium tosylate is a class III antiarrhythmic agent that prolongs the action potential duration and refractory period by blocking potassium channels. It also initially causes norepinephrine release, leading to transient hypertension and increased contractility, followed by adrenergic neuron blockade, resulting in hypotension and reduced contractility.

Bretylium tosylate is an antiarrhythmic agent that prolongs the action potential duration and refractory period in cardiac tissue. It initially causes release of norepinephrine from sympathetic nerve endings, followed by inhibition of norepinephrine release. It has class III antiarrhythmic properties and also exhibits adrenergic blockade.

Clinical Dosing

For ventricular tachycardia/fibrillation: 5-10 mg/kg IV bolus over 1-2 minutes, may repeat every 15-30 minutes up to 30 mg/kg total. Maintenance: 5-10 mg/kg IV every 6 hours or 0.5-2 mg/min continuous infusion. Intramuscular: 5-10 mg/kg undiluted, may repeat every 1-2 hours.

Intravenous: 5-10 mg/kg infused over 10-30 minutes, may repeat at 30-minute intervals up to a total of 30 mg/kg; maintenance: 1-2 mg/min as continuous IV infusion or 5-10 mg/kg every 6 hours by intermittent infusion. Intramuscular: 5-10 mg/kg undiluted, repeat every 1-2 hours as needed.

Direct Interaction